Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Wearable Microneedle Patch Monitors Antibiotic Levels in Real Time

By LabMedica International staff writers
Posted on 15 Jul 2026

Therapeutic drug monitoring for agents with narrow therapeutic windows often relies on intermittent blood draws and laboratory analysis, providing only snapshots of exposure. More...

Real-time, minimally invasive tools could give clinicians clearer insight into pharmacokinetics over hours rather than moments. Antibiotic dosing, such as with vancomycin, is a frequent target for individualized monitoring. A new study shows a lightweight wearable microneedle patch can continuously track subcutaneous antibiotic levels and transmit results to a smartphone. 

Researchers at King Abdullah University of Science and Technology (KAUST; Thuwal, Saudi Arabia) developed an aptamer-based microneedle sensing platform integrated into a 6.7-gram wearable patch. The system combines microneedle access to interstitial fluid with electrochemical biosensing, onboard electronics, wireless communication, and smartphone visualization. It is designed to move dose assessment from periodic sampling toward continuous, real-time measurement.

The patch employs an array of tiny microneedles that reach interstitial fluid just beneath the skin, enabling continuous quantification of drug concentrations. Miniaturized electronics process the signals and transmit data via Bluetooth for real-time display on a mobile device. All sensing and telemetry components are integrated into a single, lightweight format suitable for on-body use.

The technology was demonstrated using vancomycin as a model antibiotic because it must be maintained within a relatively narrow concentration range to remain safe and effective. In laboratory experiments and preclinical studies, the platform successfully tracked changes in drug levels over several hours, indicating feasibility for minimally invasive, continuous pharmacokinetic monitoring. Although tested with an antibiotic, the researchers note the sensing architecture could potentially be adapted for other medicines that require careful dose management.

The study, conducted at KAUST, was published in Device on June 18, 2026. The team stated that future work will focus on extending monitoring duration, improving long-term stability, and evaluating the platform across a broader range of applications.

“Wearable technologies have changed the way people monitor many aspects of their health, from physical activity to heart rate and sleep. This research explores whether future wearable devices could also help us understand how medicines behave inside the body. While the technology is still at an early stage, it demonstrates a new approach to monitoring therapies continuously rather than relying on occasional measurements,” said Khaled Nabil Salama, professor of electrical and computer engineering and bioengineering at KAUST and lead author of the study.

Related Links
KAUST

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.